[1]

Moura C, Leite MI, Parreira R, et al. Primary breast lymphoma[J/OL]. J Surg Case Rep, 2020, 2020(1): rjz405[2020-04-20]. https://academic.oup.com/jscr/article/2020/1/rjz405/5706871. DOI: 10.1093/jscr/rjz405.
[2] Thomas A, Link BK, Altekruse S, et al.  Primary breast lymphoma in the United States: 1975−2013[J]. J Natl Cancer Inst, 2017, 109(6): djw294-.   doi: 10.1093/jnci/djw294
[3] Nicholson BT, Bhatti RM, Glassman L.  Extranodal lymphoma of the breast[J]. Radiol Clin North Am, 2016, 54(4): 711-726.   doi: 10.1016/j.rcl.2016.03.005
[4] Frederiksen JK, Sharma M, Casulo C, et al.  Systematic review of the effectiveness of fine-needle aspiration and/or core needle biopsy for subclassifying lymphoma[J]. Arch Pathol Lab Med, 2015, 139(2): 245-251.   doi: 10.5858/arpa.2013-0674-RA
[5] Vaupel P, Schmidberger H, Mayer A.  The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression[J]. Int J Radiat Biol, 2019, 95(7): 912-919.   doi: 10.1080/09553002.2019.1589653
[6] Rahman WT, Wale DJ, Viglianti BL, et al.  The impact of infection and inflammation in oncologic 18F-FDG PET/CT imaging[J]. Biomed Pharmacother, 2019, 117: 109168-.   doi: 10.1016/j.biopha.2019.109168
[7] Kim DH, Jeong JY, Lee SW, et al.  18F-FDG PET/CT finding of bilateral primary breast mucosa-associated lymphoid tissue lymphoma[J]. Clin Nucl Med, 2015, 40(2): e148-e149.   doi: 10.1097/RLU.0000000000000545
[8] Wiseman C, Liao KT.  Primary lymphoma of the breast[J]. Cancer, 1972, 29(6): 1705-1712.   doi: 10.1002/1097-0142(197206)29:6<1705::aid-cncr2820290640>3.0.co;2-i
[9] Picasso R, Tagliafico A, Calabrese M, et al.  Primary and secondary breast lymphoma: focus on epidemiology and imaging features[J]. Pathol Oncol Res, 2020, 26(3): 1483-1488.   doi: 10.1007/s12253-019-00730-0
[10] Jung HK, Kim EK, Yun MJ, et al.  Bilateral breasts involvement in Burkitt's lymphoma detected only by FDG-PET[J]. Clin Imaging, 2006, 30(1): 57-59.   doi: 10.1016/j.clinimag.2005.08.001
[11] Santra A, Kumar R, Reddy R, et al.  FDG PET-CT in the management of primary breast lymphoma[J]. Clin Nucl Med, 2009, 34(12): 848-853.   doi: 10.1097/RLU.0b013e3181becdfc
[12] Raj SD, Shurafa M, Shah Z, et al.  Primary and secondary breast lymphoma: clinical, pathologic, and multimodality imaging review[J]. Radiographics, 2019, 39(3): 610-625.   doi: 10.1148/rg.2019180097
[13] Yang WT, Lane DL, Le-Petross HT, et al.  Breast lymphoma: imaging findings of 32 tumors in 27 patients[J]. Radiology, 2007, 245(3): 692-702.   doi: 10.1148/radiol.2452061726
[14] Rosenkrantz AB, Friedman K, Chandarana H, et al.  Current status of hybrid PET/MRI in oncologic imaging[J]. AJR Am J Roentgenol, 2016, 206(1): 162-172.   doi: 10.2214/AJR.15.14968
[15] 石琴, 张文, 付志明, 等.  肿块型与非肿块型乳腺癌MRI弥散加权成像表观扩散系数与分子生物学指标的相关性研究[J]. 国际放射医学核医学杂志, 2020, 44(4): 225-230.   doi: 10.3760/cma.j.cn121381-201903008-00019
Shi Q, Zhang W, Fu ZM, et al.  Study on the correlation between MRI diffusion-weighted imaging apparent diffusion coefficient and molecular biological indexes of mass-like and non-mass-like breast cancer[J]. Int J Radiat Med Nucl Med, 2020, 44(4): 225-230.   doi: 10.3760/cma.j.cn121381-201903008-00019
[16] Maurya V, Singh G, Ram B, et al.  Multimodality imaging features of primary breast lymphoma — a rare entity[J]. Indian J Radiol Imaging, 2019, 29(1): 85-88.   doi: 10.4103/ijri.IJRI_344_18
[17] Plecha DM, Faulhaber P.  PET/MRI of the breast[J]. Eur J Radiol, 2017, 94: A26-A34.   doi: 10.1016/j.ejrad.2017.05.006
[18] Kong EJ, Cho IH.  F-18 FDG PET/MRI findings of primary breast lymphoma in two cases: FDG PET/MRI findings of primary breast lymphoma[J]. Clin Imaging, 2015, 39(4): 682-684.   doi: 10.1016/j.clinimag.2015.01.015
[19] Zhou CY, Lv K, Lin DY, et al.  Radiological analysis of breast lymphoma: experiences from cases series studies[J]. Medicine (Baltimore), 2019, 98(48): e18101-.   doi: 10.1097/MD.0000000000018101
[20] 汤泊, 丁重阳.  原发乳腺淋巴瘤的18F-FDG PET/CT表现[J]. 影像诊断与介入放射学, 2016, 25(4): 293-296.   doi: 10.3969/j.issn.1005-8001.2016.04.006
Tang B, Ding CY.  18F-FDG PET/CT features of primary breast lymphoma[J]. Diagn Imaging Interv Radiol, 2016, 25(4): 293-296.   doi: 10.3969/j.issn.1005-8001.2016.04.006
[21] 张白露, 周清华.  原发性乳腺淋巴瘤的临床病理学及影像学特征[J]. 肿瘤, 2019, 39(5): 398-405.   doi: 10.3781/j.issn.1000-7431.2019.44.775
Zhang BL, Zhou QH.  Clinicopathological and imaging characteristics of primary breast lymphoma[J]. Tumor, 2019, 39(5): 398-405.   doi: 10.3781/j.issn.1000-7431.2019.44.775
[22]

Wienbeck S, Meyer HJ, Uhlig J, et al. Radiological imaging characteristics of intramammary hematological malignancies: results from a German multicenter study[J/OL]. Sci Rep, 2017, 7(1): 7435[2020-04-20]. https://doi.org/10.1038/s41598-017-07409-z. DOI: 10.1038/s41598-017-07409-z.
[23]

Soussan M, Orlhac F, Boubaya M, et al. Relationship between tumor heterogeneity measured on FDG-PET/CT and pathological prognostic factors in invasive breast cancer[J/OL]. PLoS One, 2014, 9(4): e94017[2020-04-20]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0094017. DOI: 10.1371/journal.pone.0094017.
[24]

Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer[J/OL]. Nat Rev Dis Primers, 2019, 5(1): 66[2020-04-20]. https://www.nature.com/articles/s41572-019-0111-2. DOI: 10.1038/s41572-019-0111-2.
[25] Paydary K, Seraj SM, Zadeh MZ, et al.  The evolving role of FDG-PET/CT in the diagnosis, staging, and treatment of breast cancer[J]. Mol Imaging Biol, 2019, 21(1): 1-10.   doi: 10.1007/s11307-018-1181-3
[26] Wang LJ, Wang DB, Chai WM, et al.  MRI features of breast lymphoma: preliminary experience in seven cases[J]. Diagn Interv Radiol, 2015, 21(6): 441-447.   doi: 10.5152/dir.2015.14534
[27]

Ou XJ, Zhang J, Wang J, et al. Radiomics based on 18F-FDG PET/CT could differentiate breast carcinoma from breast lymphoma using machine-learning approach: a preliminary study[J/OL]. Cancer Med, 2020, 9(2): 496−506[2020-04-20]. https://onlinelibrary.wiley.com/doi/10.1002/cam4.2711. DOI: 10.1002/cam4.2711.
[28] Chen W, Zhu L, Yu XZ, et al.  Quantitative assessment of metabolic tumor burden in molecular subtypes of primary breast cancer with FDG PET/CT[J]. Diagn Interv Radiol, 2018, 24(6): 336-341.   doi: 10.5152/dir.2018.17367
[29] 叶慧, 樊仁为, 唐蜜, 等.  18F-FDG PET/CT显像对乳腺肿瘤诊断临床应用价值[J]. 影像诊断与介入放射学, 2013, 22(4): 282-285.   doi: 10.3969/issn.1005-8001.2013.04.012
Ye H, Fan RW, Tang M, et al.  18F-FDG PET/CT in the diagnosis of breast tumor[J]. Diagn Imaging Interv Radiol, 2013, 22(4): 282-285.   doi: 10.3969/issn.1005-8001.2013.04.012
[30] Chicklore S, Goh V, Siddique M, et al.  Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis[J]. Eur J Nucl Med Mol Imaging, 2013, 40(1): 133-140.   doi: 10.1007/s00259-012-2247-0
[31] Harvey JA, Mahoney MC, Newell MS, et al.  ACR appropriateness criteria palpable breast masses[J]. J Am Coll Radiol, 2016, 13(11 Suppl): S31-42.   doi: 10.1016/j.jacr.2016.09.022
[32]

Jabbour G, El-Mabrok G, Al-Thani H, et al. Primary breast lymphoma in a woman: a case report and review of the literature[J/OL]. Am J Case Rep, 2016, 17: 97−103[2020-04-20]. https://www.amjcaserep.com/abstract/index/idArt/896264. DOI: 10.12659/ajcr.896264.
[33]

Liu PP, Wang KF, Jin JT, et al. Role of radiation therapy in primary breast diffuse large B-cell lymphoma in the rituximab era: a SEER database analysis[J/OL]. Cancer Med, 2018, 7(5): 1845−1851[2020-04-20]. https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.1457. DOI: 10.1002/cam4.1457.
[34] Chan HP, Liu WS, Liou WS, et al.  Comparison of FDG-PET/CT for cancer detection in populations with different risks of underlying malignancy[J]. In Vivo, 2020, 34(1): 469-478.   doi: 10.21873/invivo.11797
[35] Zhao PQ, Zhu L, Song Z, et al.  Combination of baseline total metabolic tumor volume measured on FDG-PET/CT and β2-microglobulin have a robust predictive value in patients with primary breast lymphoma[J]. Hematol Oncol, 2020, 38(4): 493-500.   doi: 10.1002/hon.2763
[36] Mayerhoefer ME, Karanikas G, Kletter K, et al.  Can interim 18F-FDG PET or diffusion-weighted MRI predict end-of-treatment outcome in FDG-avid MALT lymphoma after rituximab-based therapy?: a preliminary study in 15 patients[J]. Clin Nucl Med, 2016, 41(11): 837-843.   doi: 10.1097/RLU.0000000000001395
[37] Zhu AZ, Lee D, Shim H.  Metabolic positron emission tomography imaging in cancer detection and therapy response[J]. Semin Oncol, 2011, 38(1): 55-69.   doi: 10.1053/j.seminoncol.2010.11.012